ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Aditya Bardia, MD, MPH, FASCO
The 2-Point Signal: Apply ≥2-Point Rule
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Turning Flares Into Function: Flag Uncontrolled Disease
When to Begin FcRn: Initiation Criteria, Key Evidence
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Target Locked in gMG: Why T2T Matters
Not Just a Headache: Migraine Across Women’s Lifespan
Jelena Pavlović, MD, PhD
Amaal J. Starling, MD, FAHS, FAAN
Diagnosing and Treating IBS: It Begins With One Simple Question
Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE
Kimberly D. Orleck, PA-C
The Alloimmune Disorders of Pregnancy
Karin J. Blakemore, MD
Emilie L. Vander Haar
Cut to the Chase: Why Not Treat Endometriosis With GnRH Antagonists First?
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
Sawsan As-Sanie, MD
James A. Simon, MD, CCD, NCMP, IF, FACOG
Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
Lee P. Shulman, MD, FACMG, FACOG
Linda Bradley, MD
Samantha Denäe
Can We Talk? Optimizing Patient Buy-In to the Management of Endometriosis
Pre- and Postoperative Use of GnRH Antagonists
Strategies to Address Healthcare Disparities in Patients With Endometriosis
Melissa Simon, MD
Changing the Paradigm in the Management of Endometriosis: Moving Away From “Surgery First” to “Pharmacologic Therapy First”
Loading...
We're glad to see you're enjoying Omnia Education… but how about a more personalized experience?
Press cancel to remain on Omnia Education. Press the link below or the continue button to keep going.